Tenacibactins K–M, cytotoxic siderophores from a coral-associated gliding bacterium of the genus Tenacibaculum

  1. 1 ORCID Logo ,
  2. 1 ,
  3. 1 ,
  4. 1 ORCID Logo ,
  5. 1 ,
  6. 1 ORCID Logo and
  7. 2 ORCID Logo
1Biotechnology Research Center, Toyama Prefectural University, Imizu, Toyama 939-0398, Japan
2Faculty of Fisheries and Marine Sciences, Diponegoro University, Tembalang Campus, St. Prof. Soedarto SH., Semarang 50275, Central Java, Indonesia
  1. Corresponding author email
Associate Editor: S. Bräse
Beilstein J. Org. Chem. 2022, 18, 110–119. https://doi.org/10.3762/bjoc.18.12
Received 30 Apr 2021, Accepted 24 Nov 2021, Published 13 Jan 2022
Full Research Paper
cc by logo


HPLC/DAD-based chemical investigation of a coral-associated gliding bacterium of the genus Tenacibaculum yielded three desferrioxamine-class siderophores, designated tenacibactins K (1), L (2), and M (3). Their chemical structures, comprising repeated cadaverine–succinic acid motifs terminated by a hydroxamic acid functionality, were elucidated by NMR and negative MS/MS experiments. Compounds 13 were inactive against bacteria and a yeast but displayed cytotoxicity against 3Y1 rat embryonic fibroblasts and P388 murine leukemia cells at GI50 in submicromolar to micromolar ranges. Their iron-chelating activity was comparable to deferoxamine mesylate.


Marine organisms continue to be a prolific resource of new bioactive natural products that are applicable to pharmaceutical purposes. Especially, marine invertebrate-associated microbes are emerging as one of the hotspots for these molecules [1]. Marine invertebrates, including corals, have a sessile habit and thus are vulnerable to environmental stresses including predation and competition. They instead harbour diverse and abundant microbes on their body surface or in the tissues [2,3] and are believed to utilize secondary metabolites from the symbionts as protectants from attacks by predators, competitors, or pathogens. The ecological functions as such make marine microorganisms an attractive resource of new therapeutics, which are not found from terrestrial bioresources [4-6].

While a large majority of marine microbe-derived natural products are from fungi and actinomycetes, less attention has been paid to non-actinomycetal bacteria [6-9]. Particularly, secondary metabolites from Gram-negative bacteria are still quite limited, despite the predominance of this group in the marine environment [10,11].

The genus Tenacibaculum belongs to the family Flavobacteriaceae within the phylum Bacteroidetes. Members of this genus are Gram-negative, aerobic, motile by gliding, and commonly isolated from marine environments [12-15]. Several Tenacibaculum species are identified as fish pathogens, among which T. maritimum has been the most well-studied as an etiological agent of tenacibaculosis, a skin ulcer disease for marine fish [16]. At present, only two reports are available on the secondary metabolites from this genus [17,18]. In our continuing search for bioactive compounds from underexplored marine bacteria [19-21], a Tenacibaculum strain, isolated from a stony coral, was found to produce three metabolites, which turned out to be new cytotoxic hydroxamate-class siderophores, tenacibactins K–M (13, Figure 1).


Figure 1: Structures of tenacibactins K–M (13).

Results and Discussion

The producing strain C16-1 was isolated from a scleractinian coral of the genus Favia and was identified as a member of the genus Tenacibaculum on the basis of 16S rRNA gene sequence similarity. The same strain was cultured in three different seawater-based media, and butanolic extracts of the fermented cultures were subjected to HPLC/DAD analysis, which detected several unknown metabolites not present in our in-house UV database, showing UV end-absorption in the culture extract of A11M seawater medium. Purification of these peaks resulted in the isolation of tenacibactins K (1), L (2), and M (3).

Compound 1 was obtained as a pale brown powder. HR–ESITOFMS analysis confirmed the molecular formula of 1 to be C33H61N5O8 based on a deprotonated molecular ion [M − H] at m/z 654.4449 (Δ + 0.2 mmu for C33H60N5O8) and a sodium adduct [M + Na]+ at m/z 678.4412 (Δ + 0.0 mmu for C33H61N5O8Na). Analysis of 13C NMR and HSQC spectroscopic data obtained in DMSO-d6 established the presence of five carbonyl carbons (δC 166.2, 168.6, 171.0, 171.5, 172.0), two sp2 methines (δC 119.8, 144.5), one sp3 methine (δC 27.5), two magnetically equivalent doublet methyls (δC 22.6/δH 0.83 for six protons) (Table 1), along with many overlapping deshielded and shielded methylenes.

Table 1: 1H and 13C NMR data for tenacibactin K (1) in DMSO-d6.

position δCa, type δH, mult (J in Hz)b HMBCb,c
1a 22.6, CH3 0.83, d (6.6) 1b, 2, 3
1b 22.6, CH3 0.83, d (6.6) 1a, 2, 3
2 27.5, CH 1.48d 1a, 1b, 3, 4
3 38.56, CH2 1.12, m 1a, 1b, 2, 4, 5
4 26.9, CH2 1.22d  
5 29.4, CH2 1.22d  
6 28.88e, CH2 1.20 to ≈1.25d  
7 28.95e, CH2 1.20 to ≈1.25d  
8 29.1e, CH2 1.20 to ≈1.25d  
9 29.2e, CH2 1.20 to ≈1.25d  
10 28.7, CH2 1.33, m 12f
11 28.3, CH2 2.49, m 12f, 13f
12 144.5, CH 5.98, dt (11.4, 7.4)g 14f
13 119.8, CH 6.30, d (11.4) 11f, 14f
14 166.2, C    
16 46.7, CH2 3.48d 14, 17, 18
17 26.1, CH2 1.52d 16, 18, 19
18 23.6, CH2 1.21d  
19 28.8, CH2 1.37d 17, 18, 20
20 38.52, CH2 3.00d 18, 19, 22
21-NH   7.79, t (4.9) 20, 22
22 171.5, C    
23 30.1, CH2 2.26, t (7.4) 22, 24, 25
24 27.7, CH2 2.57, t (7.4) 22, 23, 25
25 172.0, C    
27 47.2, CH2 3.45d 25, 28, 29
28 26.1, CH2 1.50d 27, 29, 30
29 23.6, CH2 1.21d  
30 28.8, CH2 1.37d 28, 29, 31
31 38.52, CH2 2.99d 29, 30, 33
32-NH   7.81, t (5.2) 31, 33
33 171.0, C    
34 30.7, CH2 2.28, t (7.0) 33, 35, 36
35 28.0, CH2 2.16, t (7.1) 33, 34, 36
36 168.6, C    
NH or OH   8.71, brs  
NH or OH   9.71, brs  
NH or OH   10.39, brs  

aReferenced to a septet peak of DMSO-d6 at 39.5 ppm. bReferenced to a quintet peak from residual DMSO-d6 at 2.50 ppm. cFrom proton to indicated carbons. dOverlapped. eInterchangeable. fObserved in a mixed solvent CDCl3/CD3OD 3:7. gCoupling constants acquired at 50 °C.

A 1H NMR spectrum showed two olefinic resonances (δH 5.98 and 6.30) with the lowest signal intensities and others in two-to-six-fold higher intensities than these, indicating the presence of duplicated substructures. Indeed, a careful analysis of a COSY spectrum identified a pair of five-methylene fragments (H16–H20 and H27–H31) with deshielded protons/carbons at both ends (C16: δH 3.48/δC 46.7; C20: δH 3.00/δC 38.52; C27: δH 3.45/δC 47.2; C31: δH 2.99/δC 38.52), and further coupling of these fragments to exchangeable protons at δH 7.79 or 7.81, leading to the assignment of two cadaverine moieties (Figure 2). Similarly, another pair of two-methylene fragments (H23–H24 and H34–H35) were found, which respectively displayed HMBC correlations to two carbonyl carbons (δC 171.5 and 172.0; 168.6 and 171.0), thus establishing two succinic acid moieties (C22–C25; C33–C36, Figure 2). Connection of these substructures via the amide bonds with an alternate alignment of cadaverine and succinic acid was verified by HMBC correlations from the amide protons to the adjacent carbonyl carbons (H21/C22 and H32/C33) and the aminomethylene proton to another carbonyl carbon (H27/C25).


Figure 2: Key 2D-NMR correlations for 13.

The remaining COSY correlations assembled a 1,2-disubstituted double bond with a two-methylene extension (C10–C13) and an isobutyl fragment (C1a,b–C3) from the rest of the molecular parts. Quite uniquely, both of the olefinic proton resonances (H12 and H13) were broadened at 25 °C (Figure 3a). However, upon heating to 50 °C, H12 split into doublet-triplet, which allowed the extraction of 3JH12,H13 = 11.4 Hz to deduce a cis configuration. H13, in contrast, broadened more severely at the raised temperature, which was eventually attributed to the accelerated dissociation of the neighbouring hydroxamate group in a polar aprotic solvent, DMSO-d6. The isobutyl fragment showed HMBC correlations to two methylenic carbons δC 26.9 (C4) and 29.4 (C5), which provided an isohexyl fragment (Table 1). The remaining four methylenes (H6, H7, H8, H9) were not assignable from the NMR data due to signal overlapping, but were expected to be placed between the isohexyl and the alkenyl fragments, thus establishing an isopentadecenoyl moiety. The connectivity between this aliphatic chain to the tandem succinylcadaverine unit was not proven due to the lack of relevant HMBC correlations in DMSO-d6. However, when measured in a mixed solvent (CDCl3/CD3OD 3:7), the peak shape of H13 was sharpened and HMBC correlations from both of the olefinic protons and the aminomethylene H16 to a carbonyl carbon (C14: δC 166.2) were detected, which joined the C15-acyl unit to the cadaverine end (Figure 3b).


Figure 3: (a) Partial 1H NMR spectra of 1 at 25 and 50 °C in DMSO-d6; (b) magnified HMBC spectrum of 1 at 25 °C in CDCl3/CD3OD 3:7.

The structure so far assembled left H4NO3 yet to be assigned. A structural similarity of 1 to the known microbial siderophores containing the cadaverine-succinate motifs was suggestive of the presence of N-hydroxy groups in 1. Among the five amide bonds, amide protons were present at N21 and N32, thereby leaving N15, N26, and N37 as the hydroxylation sites. This assignment was supported by the 13C NMR chemical shifts. Within each cadaverine moiety, the 13C chemical shifts for the methylenes adjacent to the N-hydroxyamide group (C16: δC 46.7; C27: δC 47.2) were obviously larger than the methylenes adjacent to the amide group (C20: δC 38.52; C31: δC 38.52), consistent with the reported data for avaroferrin [22], bisucaberins [18], and nocardamines [23]. However, this trend is inversed in the hydroxamic acid terminus. The methylene carbon C35 adjacent to the hydroxamic acid group showed a smaller chemical shift (δC 28.0). The positional assignment of C34 and C35 was made by a ROESY correlation observed between H34 and 32-NH (Figure 2).

To verify the structure deduced from the NMR analysis, an MS/MS analysis was conducted [24] (Figure 4). In the negative ion mode, a precursor ion m/z 654 underwent sequential eliminations at every hydroxamate C–N bond, giving rise to ketene-terminated product ions at m/z 621 and 421, which supported the position of hydroxylation at N37 and N26 and chain lengths of each cadaverine/succinic acid module (Scheme 1, paths E1 and E2). The third elimination product, C15-ketene (structure in square brackets, Scheme 1) was not observed, but a pentadecenoate anion, appearing at m/z 239, warranted the existence of fragmentation path E3 and also the chain length of the acyl unit. Hydration of ketene to give carboxylate was also detected as an ion at m/z 439. The fragment ions m/z 232, 199, 181, and 98 were commonly detected in the MS/MS spectra for compounds 13, which appeared to be derived from the right half of the molecule by sequentially losing hydroxyamine, water, and tetrahydropyridine after formation of N-alkylated succinimide to end up as a succinimide anion. Based on these analyses, the structure of 1 was unambiguously established.


Figure 4: MS/MS spectrum of 1 acquired on a quadrupole time-of-flight mass spectrometer in the negative ion mode.


Scheme 1: MS/MS fragmentation pathway for compound 1.

Compound 2 gave molecular ions at almost the same m/z as compound 1 in the HR–ESITOFMS analysis, revealing an identical molecular formula to 1. While no significant difference was seen between the MS/MS spectra of compounds 1 and 2 (Figure 4, and Figure S19 and Scheme S20 in Supporting Information File 1), the 1H NMR spectrum of the latter exhibited coalesced olefinic signals in a deshielded region (δH 5.33) and two additional methylene resonances (H12 and H13) at δH 2.19 and 2.36, implying translocation of the double bond in the acyl portion (Table 2). The analysis of the COSY spectrum connected the above described methylenes into a bismethylene fragment, which in turn showed HMBC correlations to a carbonyl carbon (C14: δC 172.2) and two olefinic carbons (C10: δC 130.2; C11: δC 128.9), revealing the site of unsaturation at a γ,δ-position (Figure 2 and Table 2). The double bond geometry was determined to be cis on the basis of the chemical shifts of the allylic carbons (C12: δC 22.3, C9: δC 26.6) [25], which are closer to those of a (Z)-isomer (δC 22.5 and 27.2) [26] than those of an (E)-isomer (δC 28.8 and 34.8 ppm) [27]. Thus, the structure of compound 2 was determined to be a double-bond regioisomer of 1.

Table 2: 1H and 13C NMR data for tenacibactins L (2) and M (3) in DMSO-d6.

  2   3
position δCa, type δH, mult (J in Hz)b HMBCc   δCa, type δH, mult (J in Hz)b HMBCc
1a 22.6, CH3 0.83, d (6.6) 1b, 2, 3   22.6, CH3 0.83, d (6.6) 1b, 2, 3
1b 22.6, CH3 0.83, d (6.6) 1a, 2, 3   22.6, CH3 0.83, d (6.6) 1a, 2, 3
2 27.5, CH 1.48d 1a, 1b, 3, 4   27.5, CH 1.48d 1a, 1b, 3, 4
3 38.52, CH2 1.12, m 1a, 1b, 2, 4, 5   38.54, CH2 1.12, m 1a, 1b, 2, 4, 5
4 26.8, CH2 1.22d     26.8, CH2 1.22d  
5 29.3, CH2 1.22d     29.4, CH2 1.22d  
6 29.0, CH2 1.24d     28.88e, CH2 1.20 to ≈1.25d  
7 28.7, CH2 1.23d     28.92e, CH2 1.20 to ≈1.25d  
8 29.1, CH2 1.29, m 7, 9   29.07e, CH2 1.20 to ≈1.25d  
9 26.6, CH2 1.98, dt (6.0, 6.7) 7, 8, 10, 11   29.09e, CH2 1.20 to ≈1.25d  
10 130.2, CH 5.33d 8, 9, 12   29.13e, CH2 1.20 to ≈1.25d  
11 128.9, CH 5.33d 9, 12, 13   29.0, CH 1.22d  
12 22.3, CH2 2.19, dt (6.4, 7.4) 10, 11, 13, 14   24.3, CH2 1.45d 11, 13, 14
13 32.0, CH2 2.36, t (7.7) 11, 12, 14   31.8, CH2 2.31, t (7.1) 11, 12, 14
14 172.2, C       172.8, C    
16 47.2, CH2 3.44d 14, 17, 18   47.0, CH2 3.44d 14, 17, 18
17 26.1, CH2 1.48d 16, 18, 19   26.1, CH2 1.48d 16, 18, 19
18 23.6, CH2 1.20d     23.6, CH2 1.20d  
19 28.8, CH2 1.37d 17, 18, 20   28.8, CH2 1.37d 17, 18, 20
20 38.51, CH2 2.99d 18, 19, 22   38.52, CH2 2.99d 18, 19, 22
21-NH   7.78, t (5.2) 20, 22     7.80d 22
22 171.5, C       171.5, C    
23 30.0, CH2 2.26, t (7.1) 22, 24, 25   30.0, CH2 2.26d 22, 24, 25
24 27.6, CH2 2.57, t (7.0) 22, 23, 25   27.7, CH2 2.57, t (7.1) 22, 23, 25
25 172.0, C       172.1, C    
27 47.2, CH2 3.44d 25, 28, 29   47.2, CH2 3.44d 25, 28, 29
28 26.1, CH2 1.48d 27, 29, 30   26.1, CH2 1.48d 27, 29, 30
29 23.6, CH2 1.20d     23.6, CH2 1.20d  
30 28.8, CH2 1.37d 28, 29, 31   28.8, CH2 1.37d 28, 29, 31
31 38.51, CH2 2.99d 29, 30, 33   38.52, CH2 2.99d 29, 30, 33
32-NH   7.81, t (4.9) 31, 33     7.80d 33
33 171.0, C       171.0, C    
34 30.7, CH2 2.28, t (7.0) 33, 35, 36   30.7, CH2 2.28d 33, 35, 36
35 28.0, CH2 2.16, t (7.1) 33, 34, 36   28.0, CH2 2.16, t (7.2) 33, 34, 36
36 168.6, C       168.6, C    
NH or OH   8.71, brs       8.73, brs  
NH or OH   9.69, brs       9.69, brs  
NH or OH   10.39, brs       10.38, brs  

aReferenced to a septet peak of DMSO-d6 at 39.5 ppm. bReferenced to a quintet peak from residual DMSO-d6 at 2.50 ppm. cFrom proton to indicated carbons. dOverlapped. eInterchangeable.

The molecular formula of 3, determined to be C33H63N5O8 based on a deprotonated molecular ion at m/z 656.4604 (Δ 0.0 mmu for C33H62N5O8) and a sodium adduct ion at m/z 680.4567 (Δ 0.2 mmu for C33H63N5O8Na), was larger by two hydrogen atoms than that of compound 1 or 2. Indeed, olefinic resonances were absent in the NMR spectra and MS/MS fragment ions from the left half of the molecule were larger by 2 mass units than those for compounds 1 and 2 (m/z 623, 441, 423, and 241, Figure S28 and Scheme S29 in Supporting Information File 1), supporting a saturated fifteen-carbon acyl moiety in compound 3. This assignment was corroborated by substantially the same NMR data for the remaining part of 13. Thus, 3 was concluded to be a saturated congener of compounds 2 and 3.

Tenacibactins K−M (13) are new members of desferrioxamine-type hydroxamate siderophores [28]. The preceding congeners are tenacibactins A–D produced by Tenacibaculum sp. [18] and tenacibactins E–J produced by Streptomyces sp. [29]. Siderophores of this class are produced by both Gram-positive and -negative bacteria and have a linear or macrocyclic backbone [23,30] composed of alternately arranged cadaverine or putrescine and succinic acid modules with N-hydroxylation at every other amide bond. Modifications of these core structures include internal hydroxylation [30], terminal blocking by acylation [29,31,32], formation of sugar ester [33], imine oxide [34], oxime [35], or functional group transformation into a hydroxy [33] or nitro group [35]. To the best of our knowledge, compounds 13 are the first to have a hydroxamic acid terminus. Similar to the related compounds such as nocardichelins [31] and MBJ-0003 [32], compounds 13 did not show appreciable antimicrobial activity against bacteria or a yeast (see Experimental) at 50 μg/mL but exhibited cytotoxicity against 3Y1 rat embryonic fibroblasts and P388 murine leukemia cells (Table 3). Among the three compounds, 3 was the most potent, inhibiting both of the cell lines at GI50 0.60 and 0.38 μM, respectively. The iron-chelating activity of compounds 13, determined by the chrome azurol S (CAS) assay [36], was IC50 18, 49, and 37 μM, comparable to that of deferoxamine mesylate (IC50 40 μM).

Table 3: Cytotoxicity data of compounds 13.

  GI50 (μM)
cell line 1 2 3 controla
3Y1 rat embryonic fibroblasts 1.4 2.8 0.60 0.058
P388 murine leukemia 1.1 11.6 0.38 0.061

aDoxorubicin hydrochloride.


Considering the productivity of siderophores to be an essential trait for the virulence of many microbial pathogens [37], compounds 13 could also be involved in the pathogenesis of Tenacibaculum maritimum in fish, which is not well understood [38]. Although the genome size of Tenacibaculum varies from 2.5 to 7.9 Mbp, biosynthetic gene clusters for siderophores, terpenes, and non-ribosomal peptides were identified by genome mining [39], suggesting a high capability of secondary metabolism in this genus. Further investigation is underway to disclose the actual diversity of metabolites from the genus Tenacibaculum.


General experimental procedures

UV and IR spectra were measured on a Shimadzu UV-1800 spectrophotometer and a PerkinElmer Spectrum 100 spectrophotometer, respectively. NMR spectra were recorded on a Bruker AVANCE NEO 500 spectrometer using the signals of the residual solvent protons (DMSO-d6: δH 2.50; CDCl3/CD3OD: δH 7.27) and carbons (DMSO-d6: δC 39.5; CDCl3/CD3OD: δC 77.0) as internal standards. HR–ESITOFMS spectra were measured on a Bruker compact qTOF mass spectrometer. Negative ion mode MS/MS experiments were operated on the same instrument under a multiple reaction monitoring (MRM) mode with the parameter setting “isCID = 0” and “Collision = 45”. An Agilent HP1200 HPLC system equipped with a diode array detector was used for analysis and purification. The absorbance of microtitre plate wells was read on a Thermo Scientific Multiskan Sky microplate reader.


Strain C16-1 was isolated from a stony coral Favia sp. purchased from an aquarium vendor in Nagasaki, Japan, according to the method described previously [40]. The strain was identified as a member of the genus Tenacibaculum on the basis of 99.4% similarity in the 16S rRNA gene sequence (1455 nucleotides; DDBJ accession number LC498626) to Tenacibaculum aiptasiae a4T (accession number EF416572).


Strain C16-1 cultured on marine agar was inoculated into a 500 mL K-1 flask containing marine broth seed medium consisting of yeast extract (Kyokuto Pharmaceutical Industrial, Co., Ltd.) 0.2%, Tryptone (Difco Laboratories) 0.5%, dissolved in natural sea water (collected in Toyama Bay, Japan) The pH was adjusted to 7.3 before sterilization. The flasks were shaken at 30 °C for 2 days on a rotary shaker (200 rpm). The seed culture (3 mL) was transferred into 30 500 mL K-1 flasks each containing 100 mL of A11M production medium (pH 7.0) consisting of 2.5% soluble starch, 0.2% glucose, 0.5% yeast extract, 0.5% Hipolypeptone (Wako Pure Chemical Industries, Ltd), NZ amine (Wako Pure Chemical Industries, Ltd), CaCO3 0.3%, and 1% Diaion HP-20 (Mitsubishi Chemical Co.) in natural sea water. The inoculated flasks were placed on a rotary shaker (200 rpm) at 30 °C for 7 days.

Extraction and isolation

At the end of the fermentation period, 100 mL of 1-butanol were added to each flask and the flasks were shaken for 1 h. The mixture was centrifuged at 6000 rpm for 10 min and the organic layer was separated from the aqueous layer containing the mycelium. Evaporation of the solvent gave 6.54 g of extract from 3 L of culture. The extract (6.54 g) was subjected to silica gel column chromatography with a step gradient of CHCl3/MeOH 1:0, 20:1, 10:1, 4:1, 2:1, 1:1, and 0:1 (v/v). Fraction 4 (4:1) was concentrated to provide 2.46 g of a brown solid, which was further purified by ODS column chromatography with a gradient of MeCN/0.1% HCO2H 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, and 8:2 (v/v). Fraction 5 (7:3) was concentrated to dryness and the residual solid (527 mg) was applied to the preparative HPLC (Cosmosil Cholester Packed Column, 10 × 250 mm, Nacalai Tesque) using an isocratic elution with 50% MeCN in 0.1% HCO2H over 40 min at a flow rate of 4 mL/min, yielding tenacibactin K (1, 31.6 mg, tR 28.0 min), tenacibactin L (2, 2.8 mg, tR 22.0 min), and tenacibactin M (3, 18.2 mg, tR 34.4 min).

Tenacibactin K (1): pale brown powder; UV (MeOH) λmax nm (log ε): 201 (4.82) nm; IR (ATR) νmax: 3305, 2916, 2849, 1613, 1538, 1466 cm−1; 1H and 13C NMR, Table 1; HR–ESITOFMS (m/z): [M − H] calcd for C33H60N5O8, 654.4447; found, 654.4449; [M + Na]+ calcd for C33H61N5O8Na, 678.4412; found, 678.4412.

Tenacibactin L (2): pale brown powder; UV (MeOH) λmax nm (log ε): 202 (4.21) nm; IR (ATR) νmax: 3306, 2916, 2849, 1613, 1538, 1466 cm−1; 1H and 13C NMR, Table 2; HR–ESITOFMS (m/z): [M − H] calcd for C33H60N5O8, 654.4447; found, 654.4445; [M + Na]+ calcd for C33H61N5O8Na, 678.4412; found, 678.4410.

Tenacibactin M (3): pale brown powder; UV (MeOH) λmax nm (log ε): 202 (4.35) nm; IR (ATR) νmax: 3306, 2916, 2849, 1613, 1538, 1466 cm−1; 1H and 13C NMR, Table 2; HR–ESITOFMS (m/z): [M − H] calcd for C33H62N5O8, 6546.4604; found, 656.4604; [M + Na]+ calcd for C33H63N5O8Na, 680.4569; found, 680.4567.


Antimicrobial activity was examined as previously reported [41]. Kocuria rhizophila ATCC9341, Staphylococcus aureus FDA209P JC-1, Ralstonia solanacearum SUPP1541, Escherichia coli NIHJ JC-2, Rhizobium radiobacter NBRC14554, and Candida albicans NBRC0197 were used as indication strains. Cytotoxicity against 3Y1 rat embryonic fibroblasts and P388 murine leukemia cells were evaluated according to the protocols described in references [40,41].

CAS assay

Compounds 13, along with deferoxamine mesylate as a reference, were serially half-diluted in a 96-well round-bottomed microtitre plate. To each well were added 100 µL of CAS-Fe3+ solution [36]. The volumes of the vehicle solvents, DMSO for 13 and distilled water for deferoxamine mesylate, were reduced to 5% at maximum of the final test solution. After shaking the plate gently for 4 h at 25 °C, the remaining CAS-Fe3+ complex in each well was quantified by measuring the absorbance at 630 nm by a microplate reader. The results were translated into ratios of Fe3+-complexed dye at each concentration, which were plotted on single-logarithmic charts to deduce IC50 values. The tests were run in triplicate for compounds 1, 3, and deferoxamine mesylate while only a single set experiment was possible for 2 due to its limited availability.

Supporting Information

Supporting Information File 1: Copies of UV, IR, MS/MS, and NMR spectra for compounds 13.
Format: PDF Size: 3.0 MB Download


We are indebted to Prof. Yasufumi Hikichi and Dr. Ayami Kanda at Kochi University for providing R. solanacearum SUPP1541, Associate Professor Yukiko Shinozaki at National Institute of Technology, Toyama College, for providing a CAS solution, and Prof. Shinichi Ikushiro and Dr. Miu Nishikawa for allowing the use of a plate reader. P388 and 3Y1 cells were obtained from JCRB Cell Bank under an accession code JCRB0017 (Lot. 06252002) and JCRB0734 (Lot. 050295), respectively.


  1. Jiménez, C. ACS Med. Chem. Lett. 2018, 9, 959–961. doi:10.1021/acsmedchemlett.8b00368
    Return to citation in text: [1]
  2. Blockley, A.; Elliott, D. R.; Roberts, A. P.; Sweet, M. Diversity 2017, 9, 49. doi:10.3390/d9040049
    Return to citation in text: [1]
  3. Rizzo, C.; Lo Giudice, A. Diversity 2018, 10, 52. doi:10.3390/d10030052
    Return to citation in text: [1]
  4. Hou, X.-M.; Xu, R.-F.; Gu, Y.-C.; Wang, C.-Y.; Shao, C.-L. Curr. Med. Chem. 2015, 22, 3707–3762. doi:10.2174/0929867322666151006093755
    Return to citation in text: [1]
  5. Hou, X.-M.; Hai, Y.; Gu, Y.-C.; Wang, C.-Y.; Shao, C.-L. Curr. Med. Chem. 2019, 26, 6930–6941. doi:10.2174/0929867326666190626153819
    Return to citation in text: [1]
  6. Sang, V. T.; Dat, T. T. H.; Vinh, L. B.; Cuong, L. C. V.; Oanh, P. T. T.; Ha, H.; Kim, Y. H.; Anh, H. L. T.; Yang, S. Y. Mar. Drugs 2019, 17, 468. doi:10.3390/md17080468
    Return to citation in text: [1] [2]
  7. Rahman, H.; Austin, B.; Mitchell, W. J.; Morris, P. C.; Jamieson, D. J.; Adams, D. R.; Spragg, A. M.; Schweizer, M. Mar. Drugs 2010, 8, 498–518. doi:10.3390/md8030498
    Return to citation in text: [1]
  8. Blunt, J. W.; Copp, B. R.; Keyzers, R. A.; Munro, M. H. G.; Prinsep, M. R. Nat. Prod. Rep. 2016, 33, 382–431. doi:10.1039/c5np00156k
    Return to citation in text: [1]
  9. Hanif, N.; Murni, A.; Tanaka, C.; Tanaka, J. Mar. Drugs 2019, 17, 364. doi:10.3390/md17060364
    Return to citation in text: [1]
  10. Murphy, B. T.; Jensen, P. R.; Fenical, W. The Chemistry of Marine Bacteria. In Handbook of Marine Natural Products; Fattorusso, E.; Gerwick, W. H.; Taglialatela-Scafati, O., Eds.; Springer: Dordrecht, Netherlands, 2012. doi:10.1007/978-90-481-3834-0_3
    Return to citation in text: [1]
  11. Schinke, C.; Martins, T.; Queiroz, S. C. N.; Melo, I. S.; Reyes, F. G. R. J. Nat. Prod. 2017, 80, 1215–1228. doi:10.1021/acs.jnatprod.6b00235
    Return to citation in text: [1]
  12. Suzuki, M.; Nakagawa, Y.; Harayama, S.; Yamamoto, S. Int. J. Syst. Evol. Microbiol. 2001, 51, 1639–1652. doi:10.1099/00207713-51-5-1639
    Return to citation in text: [1]
  13. Kim, Y.-O.; Park, I.-S.; Park, S.; Nam, B.-H.; Park, J.-M.; Kim, D.-G.; Yoon, J.-H. Int. J. Syst. Evol. Microbiol. 2017, 67, 3268–3273. doi:10.1099/ijsem.0.002099
    Return to citation in text: [1]
  14. Park, S.; Choi, J.; Choi, S. J.; Yoon, J.-H. Int. J. Syst. Evol. Microbiol. 2018, 68, 228–233. doi:10.1099/ijsem.0.002487
    Return to citation in text: [1]
  15. Shin, S.-K.; Kim, E.; Yi, H. Int. J. Syst. Evol. Microbiol. 2018, 68, 1479–1483. doi:10.1099/ijsem.0.002692
    Return to citation in text: [1]
  16. Avendaño-Herrera, R.; Toranzo, A. E.; Magariños, B. Dis. Aquat. Org. 2006, 71, 255–266. doi:10.3354/dao071255
    Return to citation in text: [1]
  17. Jang, J.-H.; Kanoh, K.; Adachi, K.; Matsuda, S.; Shizuri, Y. J. Nat. Prod. 2007, 70, 563–566. doi:10.1021/np060502b
    Return to citation in text: [1]
  18. Fujita, M. J.; Nakano, K.; Sakai, R. Molecules 2013, 18, 3917–3926. doi:10.3390/molecules18043917
    Return to citation in text: [1] [2] [3]
  19. Sharma, A. R.; Harunari, E.; Zhou, T.; Trianto, A.; Igarashi, Y. Beilstein J. Org. Chem. 2019, 15, 2327–2332. doi:10.3762/bjoc.15.225
    Return to citation in text: [1]
  20. Karim, M. R. U.; Harunari, E.; Oku, N.; Akasaka, K.; Igarashi, Y. J. Nat. Prod. 2020, 83, 1295–1299. doi:10.1021/acs.jnatprod.0c00082
    Return to citation in text: [1]
  21. Karim, M. R. U.; Harunari, E.; Sharma, A. R.; Oku, N.; Akasaka, K.; Urabe, D.; Sibero, M. T.; Igarashi, Y. Beilstein J. Org. Chem. 2020, 16, 2719–2727. doi:10.3762/bjoc.16.222
    Return to citation in text: [1]
  22. Böttcher, T.; Clardy, J. Angew. Chem., Int. Ed. 2014, 53, 3510–3513. doi:10.1002/anie.201310729
    Return to citation in text: [1]
  23. Lee, H.-S.; Shin, H. J.; Jang, K. H.; Kim, T. S.; Oh, K.-B.; Shin, J. J. Nat. Prod. 2005, 68, 623–625. doi:10.1021/np040220g
    Return to citation in text: [1] [2]
  24. Simionato, A. V. C.; de Souza, G. D.; Rodrigues-Filho, E.; Glick, J.; Vouros, P.; Carrilho, E. Rapid Commun. Mass Spectrom. 2006, 20, 193–199. doi:10.1002/rcm.2295
    Return to citation in text: [1]
  25. Igarashi, Y.; Ootsu, K.; Onaka, H.; Fujita, T.; Uehara, Y.; Furumai, T. J. Antibiot. 2005, 58, 322–326. doi:10.1038/ja.2005.40
    Return to citation in text: [1]
  26. Wube, A. A.; Hüfner, A.; Thomaschitz, C.; Blunder, M.; Kollroser, M.; Bauer, R.; Bucar, F. Bioorg. Med. Chem. 2011, 19, 567–579. doi:10.1016/j.bmc.2010.10.060
    Return to citation in text: [1]
  27. Cai, W.; Matthews, J. H.; Paul, V. J.; Luesch, H. Planta Med. 2016, 82, 897–902. doi:10.1055/s-0042-105157
    Return to citation in text: [1]
  28. Al Shaer, D.; Al Musaimi, O.; de la Torre, B. G.; Albericio, F. Eur. J. Med. Chem. 2020, 208, 112791. doi:10.1016/j.ejmech.2020.112791
    Return to citation in text: [1]
  29. Jarmusch, S. A.; Lagos-Susaeta, D.; Diab, E.; Salazar, O.; Asenjo, J. A.; Ebel, R.; Jaspars, M. Mol. Omics 2021, 17, 95–107. doi:10.1039/d0mo00084a
    Return to citation in text: [1] [2]
  30. Nishio, T.; Tanaka, N.; Hiratake, J.; Katsube, Y.; Ishida, Y.; Oda, J. J. Am. Chem. Soc. 1988, 110, 8733–8734. doi:10.1021/ja00234a045
    Return to citation in text: [1] [2]
  31. Schneider, K.; Rose, I.; Vikineswary, S.; Jones, A. L.; Goodfellow, M.; Nicholson, G.; Beil, W.; Süssmuth, R. D.; Fiedler, H.-P. J. Nat. Prod. 2007, 70, 932–935. doi:10.1021/np060612i
    Return to citation in text: [1] [2]
  32. Kawahara, T.; Itoh, M.; Izumikawa, M.; Kozone, I.; Sakata, N.; Tsuchida, T.; Shin-ya, K. J. Antibiot. 2014, 67, 261–263. doi:10.1038/ja.2013.124
    Return to citation in text: [1] [2]
  33. Vértesy, L.; Aretz, W.; Fehlhaber, H.-W.; Kogler, H. Helv. Chim. Acta 1995, 78, 46–60. doi:10.1002/hlca.19950780105
    Return to citation in text: [1] [2]
  34. Iijima, M.; Someno, T.; Amemiya, M.; Sawa, R.; Naganawa, H.; Ishizuka, M.; Takeuchi, T. J. Antibiot. 1999, 52, 25–28. doi:10.7164/antibiotics.52.25
    Return to citation in text: [1]
  35. Iijima, M.; Someno, T.; Ishizuka, M.; Sawa, R.; Naganawa, H.; Takeuchi, T. J. Antibiot. 1999, 52, 775–780. doi:10.7164/antibiotics.52.775
    Return to citation in text: [1] [2]
  36. Schwyn, B.; Neilands, J. B. Anal. Biochem. 1987, 160, 47–56. doi:10.1016/0003-2697(87)90612-9
    Return to citation in text: [1] [2]
  37. Khan, A.; Singh, P.; Srivastava, A. Microbiol. Res. 2018, 212–213, 103–111. doi:10.1016/j.micres.2017.10.012
    Return to citation in text: [1]
  38. Pérez-Pascual, D.; Lunazzi, A.; Magdelenat, G.; Rouy, Z.; Roulet, A.; Lopez-Roques, C.; Larocque, R.; Barbeyron, T.; Gobet, A.; Michel, G.; Bernardet, J.-F.; Duchaud, E. Front. Microbiol. 2017, 8, 1542. doi:10.3389/fmicb.2017.01542
    Return to citation in text: [1]
  39. Blin, K.; Shaw, S.; Kloosterman, A. M.; Charlop-Powers, Z.; van Wezel, G. P.; Medema, M. H.; Weber, T. Nucleic Acids Res. 2021, 49, W29–W35. doi:10.1093/nar/gkab335
    Return to citation in text: [1]
  40. Sharma, A. R.; Zhou, T.; Harunari, E.; Oku, N.; Trianto, A.; Igarashi, Y. J. Antibiot. 2019, 72, 634–639. doi:10.1038/s41429-019-0192-x
    Return to citation in text: [1] [2]
  41. Li, D.; Harunari, E.; Zhou, T.; Oku, N.; Igarashi, Y. Beilstein J. Org. Chem. 2020, 16, 1869–1874. doi:10.3762/bjoc.16.154
    Return to citation in text: [1] [2]
Other Beilstein-Institut Open Science Activities